Copper chelation reprograms the tumour microenvironment to enhance immune checkpoint blockade therapy in preclinical mesothelioma
Authors:
Preprint
Abstract
Immune checkpoint blockade provides durable benefit to only a minority of patients with pleural mesothelioma. Here we investigated whether targeting copper homeostasis could enhance anti-tumour immunity and improve responses to immune checkpoint blockade. Copper homeostasis genes were upregulated in human mesothelioma, localised to malignant and stromal cells but downregulated in lymphocytes. In murine mesothelioma, these genes were dynamically regulated during anti-CTLA-4 and anti-PD-1 therapy. Treatment with copper chelator triethylenetetramine reduced intratumoural copper, increased cytotoxic lymphocytes, and enriched inflammatory genes in tumour-infiltrating myeloid and lymphoid compartments. Furthermore, copper chelation enhanced anti-CTLA-4 and anti-PD-1 therapy in immunocompetent mesothelioma mouse models, leading to durable tumour control. Our findings identify copper homeostasis as a therapeutic vulnerability in mesothelioma and support clinical evaluation of copper depletion with first-line immune checkpoint blockade.Keywords
Funding Information
- Australian Synchrotron (AS252/XFM/23805; AS243/XFM/22244)
This publication has 31 references indexed in Scilit:
- Mesothelioma survival prediction based on a six-gene transcriptomic signatureiScience, 2024
- A novel network-based method identifies a cuproplasia-related pan-cancer gene signature to predict patient outcomeHuman Genetics, 2024
- Copper transporter gene ATP7A: A predictive biomarker for immunotherapy and targeted therapy in hepatocellular carcinomaInternational Immunopharmacology, 2022
- Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in miceNature Communications, 2022
- First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743Annals of Oncology, 2022
- First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trialThe Lancet, 2021
- Copper metabolism as a unique vulnerability in cancerBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2020
- Elevated copper and oxidative stress in cancer cells as a target for cancer treatmentCancer Treatment Reviews, 2009
- Alterations in manganese, copper, and zinc contents, and intracellular status of the metal-containing superoxide dismutase in human mesothelioma cellsJournal of Trace Elements in Medicine and Biology, 2008
- Establishment of a murine model of malignant mesotheliomaInternational Journal of Cancer, 1992